EClinicalMedicine

eClinicalMedicine is a gold open access general medical journal published by Elsevier as part of The Lancet Discovery Science, launched in 2018 and covering original clinical research across all specialties, with a 2025 Journal Impact Factor of 12.8《电子临床医学》（eClinicalMedicine）是由（Elsevier）出版、隶属（The Lancet Discovery Science）的黄金开放获取综合医学期刊，2018 年创刊，刊载覆盖各专科的原创临床研究，2025 年影响因子为 12.8。

Scope

• It is a gold open access clinical journal that publishes original research to help frontline health professionals navigate the complex and rapid health transitions facing societies worldwide该刊是黄金开放获取的临床期刊，发表原创研究，帮助一线卫生专业人员应对全球社会面临的复杂而快速的健康转型。
• It helps practitioners solve the problems and challenges of health care across all communities该刊帮助从业者解决各社区医疗中的问题与挑战。
• Its coverage runs from diagnosis to treatment and from prevention to health promotion and protection其内容范围从诊断到治疗，从预防到健康促进与健康保护。^[1]
• It integrates disciplines across all specialties and across the life course with the goal of strengthening health systems该刊整合各专科与整个生命历程的学科，目标是强化卫生系统。
• It covers the whole spectrum of clinical research, from first-in-human studies through late-phase clinical trials to systematic reviews and meta-analyses该刊覆盖临床研究的完整谱系，从首次人体试验、后期临床试验到系统评价与荟萃分析。^[2]
• It also publishes global epidemiology and population health research such as worldwide prevalence studies该刊还发表全球流行病学与人群健康研究，例如全球患病率研究。^[3]
• It seeks to rethink and reframe the future of health and health care该刊力求重新思考并重新构建健康与医疗保健的未来。

History

• It was launched in 2018 as a gold open access general medical journal of the Lancet Group该刊于 2018 年作为（Lancet）集团旗下的黄金开放获取综合医学期刊创刊。
• Its inaugural issue went live in July 2018其创刊号于 2018 年 7 月上线。
• It belongs to The Lancet Discovery Science together with eBioMedicine该刊与（eBioMedicine）同属（The Lancet Discovery Science）。
• It is published by Elsevier in London and is available online only with a single electronic ISSN该刊由（Elsevier）在伦敦出版，仅在线发行，只有单一电子 ISSN。
• It received its first Journal Impact Factor for 2022 (17.033), which fell to 10.0 in 2024 and stood at 12.8 in 2025该刊 2022 年首获影响因子（17.033），2024 年降至 10.0，2025 年为 12.8。
• In 2024 it ranked eleventh among 332 general and internal medicine journals2024 年在 332 种综合与内科医学期刊中位列第 11。
• Its article publishing charge for open access is USD 6,810 excluding taxes其开放获取文章出版费为 6,810 美元（不含税）。

Editors

• The Editor-in-Chief is Claudia Schaefer, PhD, who joined the journal in 2019 after serving as a senior editor at eBioMedicine主编为 Claudia Schaefer 博士，她 2019 年加入该刊，此前在（eBioMedicine）担任高级编辑。
• Senior Editor Victoria Higgs joined the team in 2025高级编辑 Victoria Higgs 于 2025 年加入团队。
• Senior Editor Jing Yuan also joined the team in 2025高级编辑 Jing Yuan 同样于 2025 年加入团队。
• Senior Editors Sundus Shafat Ahmad and Charlotte Rowbottom are also part of the team高级编辑还包括 Sundus Shafat Ahmad 与 Charlotte Rowbottom。
• The editorial team grew from two members to eight, with six senior editors, one deputy editor and one editor-in-chief编辑团队由创建时的 2 人增至 8 人，包括 6 名高级编辑、1 名副编辑与 1 名主编。